Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?

Overview

Journal Cancers (Basel)

Publisher MDPI

Date 2025 Jan 25

PMID 39857981

Authors

A Navarro-Sabate

R Font

J A Espinas

J Sola

F Martinez-Soler

M Gil-Gil

G Vinas

A Tibau

M Borrell

M Segui

M Margeli

S Servitja

C Perez

M Domenech

M Nava

M Marin

S Gonzalez

J M Borras

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to compare estimates of adherence to oral endocrine therapy (OET) based on real-world data (RWD) and on clinical evaluation in people diagnosed with breast cancer in the public healthcare system in Catalonia (Spain).

Methods: We conducted two retrospective cohort studies. Cohort 1 (RWD) consisted of women diagnosed with breast cancer in 2021 in the public healthcare system of Catalonia (Spain). Sources of RWD were the pharmacy billing register, hospital discharge records, and the Catalan health division's central insurance registry. Nonadherence was defined as below 80% adherence in the first year of treatment. Data for cohort 2 came from two population-based cancer registries in Girona and Tarragona (Catalonia), with diagnoses from 2007 to 2011. We evaluated the impact of variables missing from RWD, such as stage and hormonal status. Analyses were performed using a chi-square test and logistic regression, with results stratified by age group and drug type.

Results: Nonadherence at one year was 10.9% in cohort 1 and 11.3% in cohort 2. When we reviewed the medical records of a selection of nonadherent women from cohort 1, we found only 59.4% had documented treatment interruptions. Reasons for interruptions in the patients from RWD cohort included adverse effects (48.8%), patient decision (40.0%), medical reasons (29.4%), and other clinical causes (14.7%). Women aged under 50 years and those receiving tamoxifen or a sequential regimen had lower adherence. Determinants associated with nonadherence were similar in both approaches used.

Conclusions: This study confirms the validity of estimating adherence with RWD from the Spanish national health system, although when combined with reviewing medical records, this may provide more reliable and higher-quality data. The RWD method provides valuable evidence to help oncologists discuss adherence with their patients.

References

Blanchette P, Lam M, Richard L, Allen B, Shariff S, Vandenberg T . Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast Cancer Res Treat. 2019; 179(1):217-227. DOI: 10.1007/s10549-019-05430-6. View

Gao P, You L, Wu D, Shi A, Miao Q, Rana U . Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. Patient Prefer Adherence. 2018; 12:887-897. PMC: 5973402. DOI: 10.2147/PPA.S167004. View

Font R, Espinas J, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I . Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. 2012; 107(8):1249-56. PMC: 3494419. DOI: 10.1038/bjc.2012.389. View

Bhimani J, OConnell K, Ergas I, Foley M, Gallagher G, Griggs J . Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer. JCO Clin Cancer Inform. 2024; 8:e2300209. PMC: 11902409. DOI: 10.1200/CCI.23.00209. View

Holmes E, Hughes D, Morrison V . Predicting adherence to medications using health psychology theories: a systematic review of 20 years of empirical research. Value Health. 2014; 17(8):863-76. DOI: 10.1016/j.jval.2014.08.2671. View

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A . Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?. Breast. 2014; 24(1):62-7. DOI: 10.1016/j.breast.2014.11.011. View

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V . Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2012; 381(9869):805-16. PMC: 3596060. DOI: 10.1016/S0140-6736(12)61963-1. View

Wang P, Benner J, Glynn R, Winkelmayer W, Mogun H, Avorn J . How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf. 2004; 13(1):11-9. DOI: 10.1002/pds.819. View

Cavazza M, Banks H, Ercolanoni M, Cukaj G, Bianchi G, Capri G . Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management. Breast Cancer Res Treat. 2020; 183(1):189-199. DOI: 10.1007/s10549-020-05748-6. View

10.

Turcu-Stiolica A, Udristoiu I, Subtirelu M, Gheorman V, Aldea M, Dumitrescu E . Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania. Front Pharmacol. 2024; 15:1345482. PMC: 10920324. DOI: 10.3389/fphar.2024.1345482. View

11.

Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo M . Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC),.... Clin Transl Oncol. 2017; 20(6):687-694. PMC: 5942338. DOI: 10.1007/s12094-017-1801-4. View

12.

Rudd P . In search of the gold standard for compliance measurement. Arch Intern Med. 1979; 139(6):627-8. View

13.

Winn A, Dusetzina S . The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016; 25(8):953-9. DOI: 10.1002/pds.4012. View

14.

Goldvaser H, Barnes T, Seruga B, Cescon D, Ocana A, Ribnikar D . Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2017; 110(1). DOI: 10.1093/jnci/djx141. View

15.

Atkins L, Fallowfield L . Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006; 42(14):2271-6. DOI: 10.1016/j.ejca.2006.03.004. View

16.

. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022; 23(3):382-392. PMC: 8885431. DOI: 10.1016/S1470-2045(21)00758-0. View

17.

Burstein H . Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. Breast. 2019; 48 Suppl 1:S89-S91. DOI: 10.1016/S0960-9776(19)31132-4. View

18.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2009; 28(3):509-18. DOI: 10.1200/JCO.2009.23.1274. View

19.

Eliassen F, Blafjelldal V, Helland T, Hjorth C, Holland K, Lode L . Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 2023; 23(1):625. PMC: 10320891. DOI: 10.1186/s12885-023-11122-8. View

20.

Liu F, Panagiotakos D . Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022; 22(1):287. PMC: 9636688. DOI: 10.1186/s12874-022-01768-6. View